+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Therapy in Oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene Induced Immunotherapy) and End-user (Hospitals, Diagnostic Centers, Research Institutes), 2022-2027

  • PDF Icon

    Report

  • 65 Pages
  • October 2022
  • Region: Global
  • GlobalData
  • ID: 5693576
The gene therapy in oncology market size was valued at US$2045 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.7% during 2022-2027. The gene therapy in oncology market report provides an executive-level overview of the gene therapy in oncology market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the global gene therapy in oncology market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The key to the growth has been the high prevalence of cancer and growing investment and funding for product development. Additionally, key strategic partnerships and mergers and acquisitions are expected to accelerate market growth. Over the forecast period, the market will witness an increase in government initiatives, favoring the gene therapy in oncology market growth.

Scope

  • This report provides overview of addressable market for gene therapy in oncology market
  • It identifies the key trends impacting growth of the market over the next 12 to 24 months, split into three categories: technology trends, macroeconomic trends, and regulatory trends.
  • It includes global market forecasts for the gene therapy in oncology industry
  • It include segmental forecasts and vendor sanpshot on leading vendors operating in or the gene therapy in oncology industry

Reasons to Buy

  • This market intelligence report offers a thorough, forward-looking analysis of the global gene therapy in oncology market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
  • Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in gene therapy in oncology markets.
  • The report also highlights key therapy type and end-user segments.
  • With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
  • The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in gene therapy in oncology markets.

Table of Contents

CHAPTER 01 Executive Summary
1.1 Gene Therapy in Oncology Market Snapshot
  • Fig.1 Market Snapshot
  • Fig.2 Key Segment Performance Snapshot
CHAPTER 02 Research Scope and Segmentation
CHAPTER 03 Technology Briefing
3.1 What is Gene Therapy?
  • Fig.3 History of Gene Therapy Development in Cancer in the 8MM
CHAPTER 04 Gene Therapy in Oncology Industry Trends Analysis
4.1 Gene Therapy in Oncology Industry Value Chain
  • Fig.4 Industry value chain analysis
4.2 Gene Therapy in Oncology Market Structure - PORTER’s Analysis
  • Fig.5 Global Gene Therapy in Oncology PORTER’s Five Force Analysis
CHAPTER 05 Global Gene Therapy in Oncology Revenue Opportunity
5.1 Global Gene Therapy in Oncology Market
  • Fig.6 Global Gene Therapy in Oncology Market - Revenue Forecast, 2020-2027 (US$ Million)
5.2 COVID-19 Impact
CHAPTER 06 Regulatory Overview
6.1 US
6.2 Europe
6.3 Japan
CHAPTER 07 Gene Therapy in Oncology Therapy Type Outlook
7.1 Gene Therapy in Oncology - Therapy Type Deep Dive
  • Fig.7 Gene Therapy in Oncology by Products- Market Overview
  • Fig.8 Gene Therapy in Oncology by Products Share - 2021 & 2027 (%)
7.1.1 ONCOLYTIC VIROTHERAPY
  • Fig.9 Oncolytic Virotherapy Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
7.1.2 GENE TRANSFER
  • Fig.10 Gene Transfer Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
7.1.3 GENE INDUCED IMMUNOTHERAPY
  • Fig.11 Gene Induced Immunotherapy Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
CHAPTER 08 Gene Therapy in Oncology End-User Outlook
8.1 Gene Therapy in Oncology - End-User Deep Dive
  • Fig.12 Gene Therapy in Oncology by Platform- Market Overview
  • Fig.13 Gene Therapy in Oncology by End-user - 2021 & 2027 (%)
8.1.1 HOSPITALS
  • Fig.14 Hospitals Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
8.1.2 DIAGNOSTIC CENTERS
  • Fig.15 Diagnostic Centers Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
8.1.3 RESEARCH INSTITUTES
  • Fig.16 Research Institutes Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
CHAPTER 09 Gene Therapy in Oncology Regional Outlook
9.1 Gene Therapy in Oncology - Regional Deep Dive
  • Fig.17 Gene Therapy in Oncology by Region- Market Overview
  • Fig.18 Gene Therapy in Oncology by Region Share - 2021 & 2027 (%)
9.1.1 NORTH AMERICA
  • Fig.19 North America Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
9.1.2 EUROPE
  • Fig.20 Europe Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
9.1.3 ASIA-PACIFIC
  • Fig.21 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
9.1.4 REST OF THE WORLD
  • Fig.22 ROW Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
CHAPTER 010 Trends, Drivers, and Challenges
10.1 Gene Therapy in Oncology - Market Trends
10.1.1 THE VIRAL VECTOR GENE THERAPY FIELD IS EXPANDING, BUT HIGH COST IS AN ISSUE
10.1.2 THE NON-VIRAL VECTOR FIELD IS HINDERED BY INEFFICIENT DELIVERY OF TRANSGENES
10.1.3 THERAPEUTIC OLIGONUCLEOTIDES HAVE MAJOR POTENTIAL BUT ARE HINDERED BY INEFFICIENT DELIVERY TO TARGET TISSUE
10.1.4 THE GENOME EDITING FIELD IS IN THE EARLY STAGES OF ITS DEVELOPMENT
10.1.5 THE ONCOLYTIC VIRUS FIELD IS HAMPERED BY LIMITATIONS OF INTRA TUMOR ADMINISTRATION, BUT NEW INVESTIGATIVE APPROACHES ABOUND
10.2 Gene Therapy in Oncology- Market Drivers
10.2.1 GROWING DEMAND FOR GENE THERAPY OVER CONVENTIONAL THERAPIES
10.2.2 ROBUST GOVERNMENT INITIATIVES AND INCREASE IN GOVERNMENT SUPPORT FOR RESEARCH IN GENE THERAPY
10.2.3 EXTENSIVE RESEARCH AND DEVELOPMENT STRATEGIES CARRIED OUT BY BIOPHARMACEUTICAL COMPANIES
10.3 Gene Therapy in Oncology - Market Challenges
10.3.1 HIGH COST OF CANCER GENE THERAPIES AND HIGH VOLUME OF CASES ARE MAJOR CONCERNS FOR PAYERS
10.3.2 SAFETY CONCERNS PERSIST, INCLUDING OFF-TARGET EFFECTS AND ADVERSE IMMUNE REACTIONS TO BACTERIAL CAS9
CHAPTER 011 Global Gene Therapy in Oncology Competitive Landscape
11.1 Gene Therapy in Oncology Competitive Landscape
11.2 Gene Therapy in Oncology Vendor Snapshot
11.2.1 COMPANY SNAPSHOT: AMGEN INC.
11.2.2 COMPANY SNAPSHOT: BRISTOL-MYERS SQUIBB CO (BMS)
11.2.3 COMPANY SNAPSHOT: GILEAD (KITE PHARMA, INC.)
11.2.4 FKD
11.2.5 GERON
11.2.6 IDERA
11.2.7 ISTARI
11.2.8 VBLS
CHAPTER 012 Appendix
12.1 Abbreviations
12.2 Methodology
12.3 Key Themes Impacting the Pharmaceutical Industry
12.4 About the Publisher
  • Contact the Publisher
List of Tables
Table 1 Key Trends Overview
Table 2 Research scope and segmentation
Table 3 Gene Therapy Classification
Table 4 Global Gene Therapy in Oncology Market
Table 5 Gene Therapy in Oncology by Therapy type, 2020-2027 ($Mn)
Table 6 Gene Therapy in Oncology by End-user, 2020-2027 ($Mn)
Table 7 Gene Therapy in Oncology by Region, 2020-2027 ($Mn)
Table 8 North America Gene Therapy in Oncology by Country, 2020-2027 ($Mn)
Table 9 Europe Gene Therapy in Oncology by Country, 2020-2027 ($Mn)
Table 10 Asia-Pacific Gene Therapy in Oncology by Country, 2020-2027 ($Mn)
Table 11 Gene Therapy in Oncology by Products, 2020-2027 ($Mn)
List of Figures
Figure 1 Market Snapshot
Figure 2 Key Segment Performance Snapshot
Figure 3 History of Gene Therapy Development in Cancer in the 8MM
Figure 4 Industry value chain Analysis
Figure 5 Global Gene Therapy in Oncology PORTER’s Five Force Analysis
Figure 6 Global Gene Therapy in Oncology Market - Revenue Forecast, 2020-2027 (US$ Million)
Figure 7 Gene Therapy in Oncology by Products- Market Overview
Figure 8 Gene Therapy in Oncology by Products Share - 2021 & 2027 (%)
Figure 9 Oncolytic Virotherapy Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 10 Gene Transfer Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 11 Gene Induced Immunotherapy Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 12 Gene Therapy in Oncology by Platform- Market Overview
Figure 13 Gene Therapy in Oncology by End-user - 2021 & 2027 (%)
Figure 14 Hospitals Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 15 Diagnostic Centers Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 16 Research Institutes Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 17 Gene Therapy in Oncology by Region- Market Overview
Figure 18 Gene Therapy in Oncology by Region Share - 2021 & 2027 (%)
Figure 19 North America Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 20 Europe Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 21 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)
Figure 22 ROW Market Revenue Opportunity Forecast, 2020-2027 (US$ Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen
  • BMS
  • Gilead (Kite Pharma, Inc.)
  • Janssen Biotech, Inc.
  • Novartis
  • Shanghai Sunway Biotech
  • Shenzen Sibiono GeneTech.